Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cyclerion Therapeutics
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has a diagnosis of primary Type I or II achalasia.
Patient has no contraindications to the performance of the baseline and postdose HRIM procedures per Investigator discretion.
You may not be if
Patient has had any prior esophageal, periesophageal, or gastric surgery, or treatment with sclerosing agent.
More than 1 pneumatic dilation procedure to a diameter of \> 2 cm in their lifetime.
Pneumatic dilation procedure to a diameter of \> 2 cm within 1 year prior to randomization. Prior bougie dilation(s) or pneumatic dilation(s) ≤ 2 cm are allowed.
Prior esophageal injection of botulinum toxin (Botox) within 6 months prior to randomization or more than 2 esophageal Botox injection procedures in their lifetime.
Patients with malignant or premalignant esophageal lesions.
Patient has taken any drug that can affect gastrointestinal (GI) motility in the 72 hours before check-in through discharge from the clinic.
Clareo Health | Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
